STIM
INSIDER BUYNeuronetics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NeutralNeuronetics posted a strong Q2 2026 earnings beat with revenue of $41.6M (+9.1% YoY), net loss narrowing to $3.4M from $10.1M, and positive adjusted EBITDA of $0.3M, while raising gross margin guidance to 48-50%. However, the company is navigating significant leadership turnover—a new CEO (March 2026), two CFO transitions within four months (departing May, permanent replacement July), and a Chief Legal Officer exit (effective August)—which creates execution risk despite near-term operational improvements.
Red flags
- •Leadership instability: three C-suite departures/transitions within five months (CEO, two CFOs, CLO)
- •NeuroStar segment revenue declined 2.7% YoY despite company-wide growth, indicating core device business headwinds
- •New CFO started July 23 after a ~2.5 month gap in permanent leadership, suggesting potential financial/reporting continuity risks during transition
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).